Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, ...

Canaccord Genuity initiates coverage on Orthofix Medical with a Buy rating and $24 price target, citing growth potential and strong financial outlook.

Julie Andrews, Orthofix's CFO, sold 4,655 shares of common stock on Jan. 16, according to a Jan. 21 SEC filing.

Fintel reports that on January 22, 2025, Canaccord Genuity initiated coverage of Orthofix Medical (NasdaqGS:OFIX) with a Buy ...

Canaccord Genuity began coverage on Orthofix International (NASDAQ:OFIX), assigning a Buy rating and setting a price target of $24.00. The firm's analysis suggests that Orthofix, following its merger ...